Clinical Annotation ID	Evidence ID	Evidence Type	Evidence URL	PMID	Summary	Score
1450375701	1450375663	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1450375663	30924126	Allele C is associated with increased response to allopurinol.	0
1043880328	827778899	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827778899	21435719	Genotype AA is associated with increased likelihood of Neurotoxicity when treated with thalidomide in people with Multiple Myeloma as compared to genotype AG.	1.5
1183680546	PA166110235	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166110235		Annotation of CPIC Guideline for peginterferon alfa-2a,peginterferon alfa-2b,ribavirin and IFNL3	100
1183680546	PA166104801	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166104801		Annotation of FDA Label for peginterferon alfa-2b and IFNL3	100
1183680546	1448568054	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448568054	27711230	Genotype CC is associated with increased sustained virological response (svr) when treated with boceprevir, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.5
1183680546	981240127	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981240127	22626609	Genotype CC is associated with increased sustained virological response (svr) when treated with boceprevir, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	3
1183680546	1447676829	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447676829	26191484	Genotype CC is associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C as compared to genotypes CT + TT.	2
1183680546	1447682452	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447682452	26670100	Allele C is associated with increased response to boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to allele T.	3.25
1183680546	1448617734	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448617734	28469811	Genotype CC is associated with increased sustained virological response (svr) when treated with boceprevir, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes CT + TT.	2.5
981419260	PA166105003	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166105003		Annotation of CPIC Guideline for allopurinol and HLA-B	100
981419260	827919454	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827919454	21545408	HLA-B *58:01 is associated with increased likelihood of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.	0
981419260	981345627	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345627	21393610	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Kidney Failure, Chronic.	3.75
981419260	981345632	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345632	21301380	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	4
981419260	981345637	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345637	19696695	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.	2.75
981419260	981345642	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345642	19018717	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with allopurinol.	3.5
981419260	981345647	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345647	18192896	HLA-B *58:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.	3
981419260	981345654	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981345654	15743917	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3
981419260	981419988	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981419988	22909208	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Arthritis, Gouty.	3.5
981419260	981420004	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/981420004	22909208	HLA-B *58:01/*58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Arthritis, Gouty.	2.75
981419260	1183682459	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183682459	23669020	HLA-B *58:01 is associated with increased risk of erythema exudativum multiforme or Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.	2.5
981419260	1183682532	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183682532	23600531	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Hyperuricemia.	2.5
981419260	1183682546	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183682546	23280169	HLA-B *58:01 is associated with Stevens-Johnson Syndrome when treated with allopurinol in men with Gout.	0.25
981419260	1183682555	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183682555	22348415	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3
981419260	1183682626	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183682626	21906289	HLA-B *58:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with allopurinol.	2
981419260	1183685075	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685075	17587850	HLA-B *58:01 is associated with Drug Hypersensitivity when treated with allopurinol in men.	0.25
981419260	1183685103	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685103	22017528	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.	3.5
981419260	1183685113	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685113	19483528	HLA-B *58:01 is associated with Epidermal Necrolysis, Toxic when treated with allopurinol in children with Hyperuricemia.	0.25
981419260	1183685121	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685121	22901319	HLA-B *58:01 is associated with drug reaction with eosinophilia and systemic symptoms when treated with allopurinol in men with Hyperuricemia.	0.25
981419260	1183685128	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685128	21790926	HLA-B *58:01 is associated with Drug Hypersensitivity when treated with allopurinol.	0.25
981419260	1184467886	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184467886	21912425	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.5
981419260	1184470833	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184470833	24858023	HLA-B *58:01 is not associated with risk of Drug Hypersensitivity when treated with allopurinol in people with Hematologic Neoplasms.	-1.75
981419260	1184748340	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184748340	25115449	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3
981419260	1184755884	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184755884	19002350	HLA-B *58:01 is not associated with increased risk of Drug Hypersensitivity and drug reaction with eosinophilia and systemic symptoms when treated with allopurinol in people with severe cutaneous adverse reactions.	-0.25
981419260	1184756798	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184756798	21393610	HLA-B *58:01 is not associated with increased risk of Exanthema when treated with allopurinol in people with Kidney Failure, Chronic.	-0.625
981419260	1184987721	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184987721	25257159	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	2.75
981419260	1184998111	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184998111	25327504	HLA-B *58:01 is associated with Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome.	1.5
981419260	1445362018	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1445362018	26104483	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.5
981419260	1447672343	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447672343	26632391	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol.	3.5
981419260	1447676605	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447676605	26655481	HLA-B *58:01 is associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol.	1
981419260	1447949095	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1447949095	26937673	HLA-B *58:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with allopurinol.	0.25
981419260	1448255668	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448255668	26996548	HLA-B *58:01 is associated with increased risk of Maculopapular Exanthema and severe cutaneous adverse reactions when treated with allopurinol.	3.75
981419260	1448256105	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448256105	27486401	HLA-B *58:01 is associated with increased risk of Maculopapular Exanthema and severe cutaneous adverse reactions when treated with allopurinol.	3.5
981419260	1448530471	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448530471	25899558	HLA-B *58:01 is associated with Stevens-Johnson Syndrome when treated with allopurinol.	0.25
981419260	1448624570	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448624570	28509689	HLA-B *58:01:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with allopurinol.	3
981419260	1448997619	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448997619	28857441	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol.	4
981419260	1449170079	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449170079	29392141	HLA-B *58:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms and Stevens-Johnson Syndrome when treated with allopurinol.	3.75
981419260	1450342159	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1450342159	30383575	HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic when treated with allopurinol.	0.25
981419260	1451211440	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1451211440	32433341	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	3.25
981419260	1446902249	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1446902249	25566896	HLA-B *58:01 is associated with Drug Hypersensitivity and Exanthema when treated with allopurinol.	0.25
981419260	1448429006	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448429006	27835909	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.	2
1449309937	PA166180457	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166180457		Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1	100
1449309937	1449275168	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449275168	27857962	Allele del is associated with increased risk of Malignant Hyperthermia when treated with isoflurane or sevoflurane in children as compared to allele GAG.	0.25
1449309937	1449310291	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449310291	11389482	Allele GAG is associated with increased risk of Malignant Hyperthermia when exposed to halothane, isoflurane or succinylcholine as compared to allele del.	0.25
1447680028	1447678770	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1447678770	26633805	Genotypes ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del is associated with increased response to capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype del/del.	3.25
1448603303	1448603169	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448603169	25558980	Genotypes AA + AG is associated with increased risk of Postoperative Nausea and Vomiting when treated with morphine in children as compared to genotype GG.	3
1444668808	1183615560	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1183615560	11593098	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to irbesartan in people with Hypertension as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.	2
1444668808	1451493552	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1451493552	11910301	Allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is not associated with response to atenolol or irbesartan in people with Hypertrophy, Left Ventricular as compared to allele del.	-1.25
1451114960	827811344	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827811344	19384296	Allele (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is not associated with survival when treated with fluorouracil in people with Colorectal Neoplasms.	-1.5
1451114960	827813351	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827813351	21919605	Genotype (TG)2/(TG)2 is associated with decreased response to fluorouracil in people with Colorectal Neoplasms.	-3.5
1451114960	769261466	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769261466	20385995	Genotypes (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3 are associated with increased progression-free survival when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype 33.	2.75
1451114960	1184468622	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184468622	20165956	Genotypes (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3 is associated with increased response to fluorouracil in people with Rectal Neoplasms as compared to genotype 33.	1.75
1451114960	1184469575	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184469575	20932673	Genotype (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 is not associated with response to fluorouracil in people with Rectal Neoplasms.	-1
1451114960	769169069	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/769169069	14522928	Genotype (TG)2/(TG)2 is associated with increased overall survival when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype (TG)3/(TG)3.	2
1451114960	769169217	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769169217	15918040	Genotype (TG)3/(TG)3 is associated with decreased response to fluorouracil in people with as compared to genotype (TG)2/(TG)2.	0
1451114960	769165179	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769165179	21167658	Genotypes (TG)2/(TG)3 + (TG)3/(TG)3 is associated with increased response to fluorouracil in people with Rectal Neoplasms as compared to genotype (TG)2/(TG)2.	-1.75
1451114960	827813447	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/827813447	20665215	Allele (TG)2 is not associated with response to fluorouracil in people with Colonic Neoplasms as compared to allele (TG)3.	-1.25
1451114960	1184886844	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1184886844	25232828	Genotype (TG)2/(TG)2 is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Esophageal Neoplasms and Stomach Neoplasms as compared to genotype (TG)2/(TG)3.	1.5
1451114960	827825053	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/827825053	16249645	Genotype (TG)2/(TG)3 is associated with increased survival when treated with cisplatin and fluorouracil in people with Stomach Neoplasms.	0.25
1451114960	769169082	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/769169082	11913730	Genotype (TG)2/(TG)2 is associated with increased response to fluorouracil in people with Colorectal Neoplasms as compared to genotypes (TG)2/(TG)3 + (TG)3/(TG)3.	1.5
1451114960	1449155868	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449155868	28972045	Genotype (TG)2/(TG)2 is associated with increased overall survival when treated with cisplatin, epirubicin and fluorouracil in people with Esophageal Neoplasms or Stomach Neoplasms as compared to genotypes (TG)2/(TG)3 + (TG)3/(TG)3.	2.5
1449566379	1449566369	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449566369	29925376	Genotypes AA + AG is associated with increased response to hydrochlorothiazide in people with Hypertension as compared to genotype GG.	2.5
1448427588	1448427423	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448427423	27168101	GSTT1 null/null is associated with increased risk of Neutropenia when treated with clozapine as compared to GSTT1 non-null/non-null + non-null/null.	2.75
1183621000	PA166119846	Guideline Annotation	https://www.pharmgkb.org/guidelineAnnotation/PA166119846		Annotation of CPIC Guideline for dapsone, methylene blue, pegloticase, rasburicase, tafenoquine, toluidine blue and G6PD	100
1183621000	1183685142	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685142	22190578	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in men with Burkitt Lymphoma.	0.125
1183621000	1183685166	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685166	22015451	G6PD deficiency is associated with Hemolysis when treated with methylene blue and rasburicase in people with Neoplasms.	0.125
1183621000	1183685176	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685176	18561168	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in children with Hyperuricemia.	0.125
1183621000	1183685188	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685188	16204390	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in men with Kidney Failure, Acute.	0.125
1183621000	1183685208	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685208	2019023	G6PD deficiency is associated with Anemia, Hemolytic when treated with rasburicase in men with Hyperuricemia.	0.125
1183621000	1183685218	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685218	2019023	G6PD deficiency is associated with Anemia, Hemolytic when treated with rasburicase in children with Neoplasms.	0.125
1183621000	1183685222	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685222	9369411	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	0.125
1183621000	1183685227	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685227	12075750	G6PD deficiency is associated with Hemolysis when treated with rasburicase in people with Neoplasms.	0.0
1183621000	1183685232	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685232	22573495	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in men with Hyperuricemia.	0.125
1183621000	1183685242	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685242	17387701	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in children with Burkitt Lymphoma.	0.125
1183621000	1183685251	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685251	12942574	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in children with Neoplasms.	0.0
1183621000	1183685257	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183685257	23860572	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in men with Leukemia, Lymphoid.	0.125
1183621000	1184169040	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184169040	24750455	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in women with Tumor Lysis Syndrome.	0.125
1183621000	1184515920	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515920	25115783	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in children with Leukemia.	0.125
1183621000	1444710866	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444710866	25988058	G6PD deficiency is associated with Anemia, Hemolytic when treated with rasburicase.	0.125
1183621000	1444713834	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444713834	26033222	G6PD deficiency is associated with Anemia, Hemolytic and Methemoglobinemia when treated with methylene blue and rasburicase.	0.125
1183621000	1448634792	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1448634792	28370399	G6PD deficiency is associated with Methemoglobinemia when treated with rasburicase in children with Tumor Lysis Syndrome.	0.125
1183621000	1449161310	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1449161310	29290749	G6PD deficiency is associated with Anemia, Hemolytic when treated with rasburicase in children with Precursor T-Cell Lymphoblastic Leukemia-Lymphoma.	0.125
1183621000	1183620431	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1183620431	20196170	G6PD A-202A_376G is associated with Hemolysis when exposed to rasburicase in men with Burkitt Lymphoma.	0.25
1183621000	1184515977	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515977	23209099	G6PD Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham (assigned as deficiency phenotype) is associated with Hemolysis and subsequent death when treated with rasburicase in children with Hyperuricemia.	0.25
1183621000	1184515983	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1184515983	19654083	G6PD Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham (assigned as deficiency phenotype) is associated with adverse reaction due to rasburicase in men with Neoplasms.	0.25
1183621000	1444699847	Variant Phenotype Annotation	https://www.pharmgkb.org/variantAnnotation/1444699847	23989394	G6PD A- 202A_376G (assigned as deficiency phenotype) is associated with Methemoglobinemia when treated with rasburicase in infants with Kidney Failure, Acute.	0.25
1447979749	PA166152939	Label Annotation	https://www.pharmgkb.org/labelAnnotation/PA166152939		Annotation of FDA Label for ivacaftor / lumacaftor and CFTR	100
1447979749	1449192069	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192069	29126871	Allele del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.	1.0
1447979749	1449192108	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192108	28606620	Genotype del/del is associated with response to ivacaftor and lumacaftor in children with Cystic Fibrosis.	2.5
1447979749	1449192508	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192508	27898234	Genotype CTT/del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.	3.0
1447979749	1449192520	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192520	27898234	Genotype CTT/del is not associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.	-1.5
1447979749	1449192588	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192588	25981758	Genotype del/del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.	2.5
1447979749	1449192632	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192632	27805836	Genotype del/del is associated with response to ivacaftor and lumacaftor in children with Cystic Fibrosis.	2.75
1447979749	1449192645	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192645	27805836	Genotype del/del is not associated with response to ivacaftor and lumacaftor in children with Cystic Fibrosis.	-1.25
1447979749	1449192689	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192689	29327948	Genotype del/del is associated with response to ivacaftor and lumacaftor in people with Cystic Fibrosis.	2.75
1447979749	1449192749	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192749	29451946	Genotype del/del is associated with response to ivacaftor and lumacaftor in men with Cystic Fibrosis.	2.5
1447979749	1449191920	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449191920	28325531	Genotype del/del is associated with response to ivacaftor / lumacaftor in people with Cystic Fibrosis.	2.25
1447979749	1449192352	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1449192352	27334259	Allele del is associated with response to ivacaftor / lumacaftor.	0.25
1447979749	1446903870	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903870	24973281	Genotype del/del is associated with response to ivacaftor / lumacaftor in people with Cystic Fibrosis.	2.0
1447979749	1446903951	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903951	24973281	Genotype del/del is associated with response to ivacaftor / lumacaftor in people with Cystic Fibrosis.	2.5
1447979749	1446903975	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1446903975	24973281	Genotype CTT/del is not associated with response to ivacaftor / lumacaftor in people with Cystic Fibrosis.	-0.375
1447979749	1448107229	Variant Drug Annotation	https://www.pharmgkb.org/variantAnnotation/1448107229	27298017	Genotype del/del is associated with increased response to ivacaftor / lumacaftor in people with Cystic Fibrosis as compared to genotypes CTT/CTT + CTT/del.	2.5
1447979749	1451123748	Variant Functional Assay Annotation	https://www.pharmgkb.org/variantAnnotation/1451123748	23275066	Allele del is associated with decreased catalytic activity of CES1 when assayed with 2-oxo-clopidogrel or clopidogrel as compared to allele CTT.	0.0
